## ğŸ§¾ Model Card â€” Severity Classifier (BioBERT)

Model Name: ADEGuard-BioBERT-Severity Classifier 

Version: 1.0

Authors / Maintainers: Suganya G

### **Model Type:** Sequence Classification (Severity Prediction) based on BioBERT

### **Intended Use**
**Primary Purpose:**
Classify the *severity level* (Mild / Moderate / Severe) of an identified Adverse Drug Event (ADE) described in free-text clinical reports or VAERS narratives.

**Applications:**
* ğŸ” Prioritize high-severity ADE cases for human review.
* ğŸ¥ Support hospital pharmacovigilance and safety signal detection.
* ğŸ“ˆ Input for dashboards and severity trend analytics (ADEGuard).
* ğŸ”— Downstream integration with ADE/DRUG NER output to create full event triplets: `(DRUG, ADE, SEVERITY)`.

**Input:**
Short free-text span or sentence describing an ADE (e.g., `"Patient experienced severe headache after Moderna booster"`).

**Output:**
Severity class prediction:
* **0 â€” Severe**
* **1 â€” Moderate**
* **2 â€” Mild**

### **Training Details**
**Base Model:** `dmis-lab/biobert-base-cased-v1.1`

**Framework:** Hugging Face Transformers (PyTorch)
**Training Dataset:**

* Derived from VAERS vaccine reports (2020â€“2025).
* Severity labels derived from *weak supervision* (Snorkel) + manual corrections.

**Weak Labels Source:**
* Snorkel LFs on structured fields: `DIED`, `HOSPITAL`, `L_THREAT`, `DISABLE`.
* Text heuristics: `"mild"`, `"moderate"`, `"severe"`,  etc.

**Training Setup:**
* Train/val/test split = 70/15/15 stratified.
* Learning rate = 2e-5, batch size = 16, epochs = 3.
* Optimizer: AdamW, Weight decay = 0.01.
* Evaluation metric: Weighted F1.


**Confusion Insights:**
* Moderate vs Mild occasionally confused (context overlap).
* Severe class stable, mainly influenced by hospitalization or death indicators.

âš ï¸ *Performance may vary with text domain or missing contextual cues (e.g., "rash" alone vs "rash requiring ER visit").*


### **Limitations**
* Domain-specific: Trained primarily on VAERS vaccine narratives.
* No Causality: Predicts severity, not whether drug caused ADE.
* Ambiguous Phrases: Phrases like â€œfelt badâ€ or â€œtiredâ€ may yield uncertain predictions.
* Dependent on upstream NER: Requires correctly extracted ADE spans.
* No long-text context: Model trained on snippets (<128 tokens).


### **Ethical and Responsible Use**
* ğŸ§‘â€âš•ï¸ Intended for *research and pharmacovigilance professionals*.
* âš ï¸ *Not for clinical diagnosis or automated patient triage.*
* ğŸ”’ Data used are *de-identified* VAERS reports in compliance with FDA/CDC policies.
* Transparency: Weak labels introduced probabilistic uncertaintyâ€”outputs should be verified by experts.


### **Model Outputs Example**
| Input                                                | Predicted Severity |
| ---------------------------------------------------- | ------------------ |
| â€œPatient developed mild swelling at injection site.â€ | Mild               |
| â€œHospitalized due to severe allergic reaction.â€      | Severe             |
| â€œFever and headache lasted 2 days.â€                  | Moderate           |



### **Intended Integration**
Part of the **ADEGuard Clinical Safety Pipeline**

### **Metrics**
### **Classifier Training Summary**

| Epoch | Training Loss | Validation Loss | Accuracy | F1 Score |
| ----- | ------------- | --------------- | -------- | -------- |
| 1     | 0.3282        | 0.1849          | 94.25%   | 93.99%   |
| 2     | 0.1664        | 0.1932          | 94.25%   | 94.13%   |
| 3     | 0.1352        | 0.2115          | 94.43%   | 94.29%   |

**Test Set Performance:**

* Loss: 0.2307
* Accuracy: 94.18%
* F1 Score: 94.08%

**Interpretation:**

* Training loss decreases, showing effective learning.
* Slight validation loss rise in later epochs but accuracy remains high â†’ good generalization.
* Model performs reliably for ADE severity classification.



### **Citation / Acknowledgment**
> Built using `dmis-lab/biobert-base-cased-v1.1` and VAERS 2020â€“2025 public data.

> Weak supervision inspired by Snorkel (Ratner et al., 2020).

> Developed as part of ADEGuard for pharmacovigilance and safety monitoring.

